CoChat

TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss

Open access
Hu, Lianxin, Xie, Haibiao, Liu, Xijuan, Potjewyd, Frances, James, Lindsey I., Wilkerson, Emily M., Herring, Laura E., Xie, Ling, Chen, Xian, Cabrera, Johnny Castillo, Hong, Kai, Liao, Chengheng, Tan, Xianming, Baldwin, Albert S., Gong, Kan, Zhang, Qing · 2020 · Cancer Discovery
Cited by 108

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

TANK binding kinase 1 (TBK1) is an important kinase involved in the innate immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau (VHL) loss or hypoxia in cancer cells. Tumors from patients with kidney cancer with VHL loss display elevated TBK1 phosphorylation. Loss of TBK1 via genetic ablation, pharmacologic inhibition, or a new cereblon-based proteolysis targeting chimera specifically inhibits VHL-deficient kidney cancer cell growth, while leaving VHL wild-type cells intact. TBK1 depletion also significantly blunts kidney tumorigenesis in an orthotopic xenograft model in vivo. Mechanistically, TBK1 hydroxylation on Proline 48 triggers VHL as well as the phosphatase PPM1B binding that leads to decreased TBK1 phosphorylation. We identify that TBK1 phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation. Our results establish that TBK1, distinct from its role in innate immune signaling, is a synthetic lethal target in cancer with VHL loss. Significance: The mechanisms that lead to TBK1 activation in cancer and whether this activation is connected to its role in innate immunity remain unclear. Here, we discover that TBK1, distinct from its role in innate immunity, is activated by VHL loss or hypoxia in cancer. See related commentary by Bakouny and Barbie, p. 348. This article is highlighted in the In This Issue feature, p. 327

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0837

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 108

Metadata

Authors
Hu, L., Xie, H., Liu, X., Potjewyd, F., James, L. I., Wilkerson, E. M., Herring, L. E., Xie, L., Chen, X., Cabrera, J. C., Hong, K., Liao, C., Tan, X., Baldwin, A. S., Gong, K., & Zhang, Q.
Venue
Cancer Discovery
Published
2020-03-01
Volume
10
Issue
3
Pages
460-475
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2994346287
Cited by
108
References
12
FWCI
7.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0837
The paper
Hu, L., Xie, H., Liu, X., Potjewyd, F., James, L. I., Wilkerson, E. M., Herring, L. E., Xie, L., Chen, X., Cabrera, J. C., Hong, K., Liao, C., Tan, X., Baldwin, A. S., Gong, K., & Zhang, Q. (2020). TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0837

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.